Cat: PAX2000-12143

Recombinant Human TRIM22 Protein,His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    TRIM22

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Alternative Names

    TRIM22; RNF94; STAF50; E3 ubiquitin-Protein ligase TRIM22; EC 2.3.2.27; 50 kDa-stimulated trans-acting factor; RING finger Protein 94; RING-type E3 ubiquitin transferase TRIM22; Staf-50; Tripartite motif-containing Protein 22

  • Species

    Human

  • Source

    E. coli

  • Tag

    His tag N-Terminus

  • Purity

    Greater than 90% as determined by SDS-PAGE.

  • Uniprot

    Q8IYM9

  • Expression Region

    1-498 aa

  • AA Sequence

    MDFSVKVDIE KEVTCPICLE LLTEPLSLDC GHSFCQACIT AKIKESVIIS RGESSCPVCQ TRFQPGNLRP NRHLANIVER VKEVKMSPQE GQKRDVCEHH GKKLQIFCKE DGKVICWVCE LSQEHQGHQT FRINEVVKEC QEKLQVALQR LIKEDQEAEK LEDDIRQERT AWKNYIQIER QKILKGFNEM RVILDNEEQR ELQKLEEGEV NVLDNLAAAT DQLVQQRQDA STLISDLQRR LRGSSVEMLQ DVIDVMKRSE SWTLKKPKSV SKKLKSVFRV PDLSGMLQVL KELTDVQYYW VDVMLNPGSA TSNVAISVDQ RQVKTVRTCT FKNSNPCDFS AFGVFGCQYF SSGKYYWEVD VSGKIAWILG VHSKISSLNK RKSSGFAFDP SVNYSKVYSR YRPQYGYWVI GLQNTCEYNA FEDSSSSDPK VLTLFMAVPP CRIGVFLDYE AGIVSFFNVT NHGALIYKFS GCRFSRPAYP YFNPWNCLVP MTVCPPSS

  • Molecular Weight

    56.9 kDa

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

TRIM22, a member of the Tripartite Motif (TRIM) protein family, has garnered significant attention due to its multifaceted roles in immune response and viral defense mechanisms. This protein is characterized by a RING finger domain, which is integral to its E3 ubiquitin ligase activity, allowing it to modulate various cellular pathways through protein degradation and modification. Previous studies have indicated that TRIM22 plays a crucial role in restricting viral replication, particularly against HIV and other RNA viruses, by targeting viral proteins for ubiquitination and subsequent degradation. Additionally, TRIM22 has been implicated in the regulation of interferon signaling pathways, enhancing the host's antiviral response. The exploration of TRIM22 as a recombinant protein has advanced our understanding of its structural and functional properties, providing insights into its potential as a therapeutic target for viral infections and its involvement in various diseases, including cancer and autoimmune disorders. Researchers are actively investigating the mechanistic pathways influenced by TRIM22, aiming to harness its properties for innovative therapeutic strategies. This evolving field of study underscores the importance of TRIM22 in host-pathogen interactions and its potential as a biomarker for disease prognosis and treatment outcomes. As we delve deeper into the complexities of TRIM22, the developments in recombinant protein technology offer promising avenues for the design of novel vaccines and antiviral therapies, making it a pivotal focus of current biomedical research.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US